AI-designed drugs enter human trials

Isomorphic Labs, a startup spun out from Google's DeepMind, is advancing its AI-developed drug candidates into human clinical trials. President Max Jaderberg announced the company has cultivated a substantial and promising portfolio of novel medications. This development marks a significant milestone in the application of artificial intelligence within the pharmaceutical industry, potentially accelerating the discovery and development of new treatments for various diseases.